10 Hot Small Caps Primed For A Winning Streak (Part I)

View HIIQ Price Target & Analyst Ratings Details

2. Manitowoc Company

Manitowoc (NYSE:MTWproduces cranes for the construction industry. In the last month, both JP Morgan and SunTrust Robinson upgraded their MTW ratings. Why? Well SunTrust Robinson’s Charles Brady (Profile & Recommendations) left the company’s Crane Day “impressed” with the pace and breadth of new product development. He sees meaningful earnings accretion for Manitowoc on the horizon, and raised his 2018 and 2019 EPS estimates. Brady is now modelling for 47c and $1.44 up from 32c and $1.22, respectively. This comes with a $33 price target (28% upside potential).

Five analysts have published buy ratings in the last three months, vs just 1 hold rating. These analysts (on average) see prices rising 39% to $36. View MTW Price Target & Analyst Ratings Details.

3. Gray Television 

Atlanta based TV-station owner Gray Television (NYSE:GTN) is buzzing right now. The company has just snapped up Raycom Media in a $3.65 billion deal. “The deal positives appear to vastly outweigh the associated risks” stated top Benchmark analyst Daniel Kurnos (Profile & Recommendations).

“The merger will bring Gray’s national reach to 24%, effectively eliminating the one major criticism of the otherwise strong operator, while enhancing projected free cash flow by over 80%” he explains. Moreover, it meshes two highly complementary station portfolios from both a quality and culture perspective. Kurnos’ bullish $26 price target indicates 65% upside potential- placing him slightly above the Street:

View GTN Price Target & Analyst Ratings Details

4. uniQure NV

Breaking news, uniQure  (Nasdaq:QUREhas just announced it has enrolled its 1st patient in the pivotal phase III study of AAV5-based gene-based therapy, AMT-061, for hemophilia B. The stock is a Chardan Top Pick for 2018. Five-star Chardan analyst Gbola Amusa (Profile & Recommendations) writes that QURE “will likely be first to market for AAV-based hemophilia B [gene therapy].” Bear in mind that Hemophilia B is one of the largest orphan drug markets in the US. His $50 price target indicates 33% upside potential.

View single page >> |

Disclaimer: TipRanks is an independent cloud based service that measures and ranks digitally published financial advice. TipRanks' natural language processing (NLP) algorithms aggregate and ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.